Slide 1: Fourth Quarter and Year-End 2021 Financial Results & Business Update
Fourth Quarter and Year-End 2021 Financial Results & Business Update February 16, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Agenda Introduction Sandy Coombs, SVP, Investor Relations & Corporate Affairs Welcome Richard Pops, Chief Executive Officer Q4 & FY 2021 Financial Results; 2022 Financial Expectations Iain Brown, Chief Financial Officer Q4 & FY 2021 Commercial Review Todd Nichols, Chief Commercial Officer R&D Pipeli
Slide 4: Three Strategic Priorities
Development Pipeline Advance pipeline of neuroscience and oncology candidates Commercial Grow commercial portfolio of proprietary products Three Strategic Priorities Grounded in Strong Culture of Responsibility Profitability Drive long-term profitability Patient-focused ethos and strong commitment t
Slide 5: 2021 Key Achievements
Continued Board of Directors refreshment efforts Appointed two new independent Directors Announced retirement of two longer-serving Directors Initiated declassification of Board of Directors Development Pipeline Commercial Execution 2021 Key Achievements Advanced Core Business Objectives Profitabili
Slide 6: FY 2021 Financial Results Summary
FY 2021 Financial Results Summary In millions In millions In millions
Slide 7: Q4 2021 Revenue Summary
Q4 2021 Revenue Summary Amounts in the table above do not sum due to rounding. *Inclusive of ARISTADA INITIO®
Slide 8: 2021 Revenue Summary
2021 Revenue Summary Amounts in the table above do not sum due to rounding. *Inclusive of ARISTADA INITIO®
Slide 9: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations FY’21 year-over-year net sales increased 11% to $343.9M, driven by unit growth of 10% Gross-to-net deductions: 51.5% in FY’21, compared to 49.9% in FY’20 Inventory levels increased sequentially by ~$3M, in line with typical seasonal patterns FY’22 net sales exp
Slide 10: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations FY’21 year-over-year net sales increased 14% to $275.4M, driven by unit growth of 11% Gross-to-net deductions: 53.7% in FY’21, compared to 53.3% in FY’20 Inventory levels increased by ~$3M, which is expected to be drawn down in Q1’22 FY’22 net sales expected to
Slide 11: ARISTADA Prescription Growth Trends
ARISTADA® Prescription Growth Trends Q4’21 year-over-year growth of 13% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q4’21 year-over-year growth of 4% Market share: TRx MOT: 9.8% of atypical LAI market prescriptions in Q4’21 ARISTADA Quarterly TR
Slide 12: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations Q4’21 net sales of $8.2M Gross-to-net deductions: ~35% FY’22 net sales expected to range from $55M - $75M† Expect gross-to-net deductions of ~40% in FY’22 *Source: IQVIA NPA Weekly † These expectations are provided by the company in its Form 8-K filed with the S
Slide 13: Alkermes: 2022 Financial Expectations
Alkermes: 2022 Financial Expectations* *These expectations are provided by the Company in its Form 8-K filed with the SEC on Feb. 16, 2022 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. These expectations assume improv
Slide 14: Revised Profitability Targets
Revised Profitability Targets Profitability Targets ~30% 11%** *The Company is not providing reconciliations of, or comparable GAAP measures for, forward-looking non-GAAP profitability targets because the comparable GAAP measures are not determinable without unreasonable efforts due to the inherent
Slide 15: Looking Ahead: 2022 Strategic Priorities
Looking Ahead: 2022 Strategic Priorities Execute successful LYBALVI® launch and continue to establish payer access profile Drive growth of VIVITROL® in alcohol dependence indication and increase ARISTADA® share of aLAI market Commercial Portfolio Nemvaleukin Early-stage Pipeline Financial Advance en
Slide 16: Important Additional Information and Where to Find It
Important Additional Information and Where to Find It The Company intends to file a definitive proxy statement, accompanying proxy card and other relevant documents with the SEC in connection with the solicitation of proxies for the Company’s 2022 annual general meeting of shareholders. BEFORE MAKIN
Slide 17: Appendix: GAAP to Non-GAAP Adjustments
Appendix: GAAP to Non-GAAP Adjustments
Slide 18: www.alkermes.com
www.alkermes.com